natgillin/translations-raw huggingface dataset:
The CURE study included 12,562 patients with non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), and presenting within 24 hours of onset of the most recent episode of chest pain or symptoms consistent with ischaemia.
Studija CURE uključivala je 12 562 bolesnika s akutnim koronarnim sindromom bez elevacije ST- segmenta (nestabilna angina ili non-Q infarkt miokarda), koji su u zadnja 24 sata imali epizodu boli u prsištu ili simptome ishemije.
The current (July 2006) ANRS AC-11 algorithm for fosamprenavir / ritonavir defines resistance as the presence of the mutations V32I+I47A/V, or I50V, or at least four mutations among: L10F/I/V, L33F, M36I, I54A/L/M/S/T/V, I62V, V82A/C/F/G, I84V and L90M and is associated with increased phenotypic resistance to fosamprenavir with ritonavir as well as reduced likelihood of virological response (resistance).
Trenutno važeći (iz srpnja 2006.) ANRS AC-11 algoritam za fosamprenavir/ritonavir definira rezistenciju kao prisutnost mutacija V32I+I47A/V ili I50V, ili barem četiri mutacije od: L10F/I/V, L33F, M36I, I54A/L/M/S/T/V, I62V, V82A/C/F/G, I84V i L90M, i povezan je s povećanom fenotipskom rezistencijom na fosamprenavir s ritonavirom kao i sa smanjenjem vjerojatnošću virološkog odgovora (rezistencija).
The current (July 2006) ANRS AC-11 algorithm for fosamprenavir / ritonavir defines resistance as the presence of the mutations V32I+I47A/V, or I50V, or at least four mutations among: L10F/I/V, L33F, M36I, I54A/L/M/S/T/V, I62V, V82A/C/F/G, I84V and L90M and is associated with increased phenotypic resistance to fosamprenavir with ritonavir as well as reduced likelihood of virological response (resistance).
Trenutno važeći (iz srpnja 2006.) ANRS AC-11 algoritam za fosamprenavir/ritonavir definira rezistenciju kao prisutnost mutacija V32I+I47A/V, ili I50V ili barem četiri mutacije od: L10F/I/V, L33F, M36I, I54A/L/M/S/T/V, I62V, V82A/C/F/G, I84V i L90M, i povezan je s povećanom fenotipskom rezistencijom na fosamprenavir s ritonavirom kao i sa smanjenjem vjerojatnošću virološkog odgovora (rezistencija).
The current dose of metformin and thiazolidinedione can be continued unchanged.
Postojeća doza metformina i tiazolidindiona može se nastaviti primjenjivati bez promjene.
The current understanding of the benefits and risks of cytoreductive surgery in the management of patients with malignant gliomas;
Trenutni stavovi o koristima i rizicima citoredukcijske kirurgije u liječenju bolesnika s zloćudnim gliomima;
The current understanding of the benefits and risks of cytoreductive surgery in the management of patients with malignant gliomas;
Trenutni stavovi o koristima i rizicima citoredukcijske kirurgije u liječenju bolesnika sa zloćudnim gliomima;
The current warning in the SmPC outlines that the initial prescription and dispensing of Erivedge should occur within 7 days of a negative pregnancy test.
U trenutnom upozorenju u Sažetku opisa svojstava lijeka navodi se da se Erivedge mora prvi puta propisati i izdati unutar 7 dana od negativnog nalaza testa na trudnoću.
The currently available data both in vitro and in patients suggest that HBV expressing the adefovir- associated resistance mutation rtN236T is susceptible to lamivudine.
Trenutno raspoloživi podaci dobiveni i in vitro i od pacijenata ukazuju na to da je HBV koji izražava mutaciju rtN236T povezanu s rezistencijom na adefovir osjetljiv na lamivudin.
The currently available evidence was sufficient to show that Zykadia could be of benefit in these circumstances, although further data to confirm this are awaited.
Trenutno dostupni dokazi bili su dovoljni kako bi se dokazalo da lijek Zykadia može biti koristan u tim okolnostima, iako se očekuju daljnji podaci koji to potvrđuju.
The customer or the user of the administration system can help prevent electromagnetic interference by maintaining a minimum distance between portable and mobile RF communications equipment (transmitters) and the administration system as recommended below, according to the maximum output power of the communication equipment.
Kupac ili korisnik sustava za primjenu može pridonijeti sprječavanju elektromagnetskih smetnji održavanjem minimalne udaljenosti između prijenosnih i mobilnih RF komunikacijskih uređaja (odašiljača) i sustava za primjenu sukladno preporukama u nastavku, koje se temelje na maksimalnoj izlaznoj snazi komunikacijskih uređaja.
The customer or the user of the administration system should assure that it is used in such an environment.
Kupac ili korisnik sustava za primjenu mora se pobrinuti da se on koristi u takvom okruženju.
The customer or the user of the administration system should assure that it is used in such an environment.
Kupac ili korisnik sustava za primjenu mora se pobrinuti da se sustav za primjenu koristi u takvom okruženju.
The cut off point for discriminating Helicobacter pylori-negative and positive patients is determined to be -value of 4 ‰, which means that an increase of the -value by more than 4 ‰ indicates an infection.
Δδ-vrijednost od 4‰ granična je između pozitivnog i negativnog nalaza pri dokazivanju Helicobacter pylori, što znači da Δδ-vrijednost veća od 4‰ upućuje na infekciju.
The CVMP agreed that the periodic safety update report (PSUR) cycle for Aivlosin would be re- started for submission of 6 monthly reports (covering all authorised presentations of the product) for the next two years, followed by yearly reports for the subsequent two years and thereafter at three yearly intervals.
Odbor za veterinarsko-medicinske proizvode (CVMP) dao je suglasnostza ponovno pokretanje ciklusaperiodičnih ažuriranih izvješća o neškodljivosti (PSUR)gdje će se podnositi polugodišnja izvješća (koja obuhvaćaju sve odobreneprezetacije proizvoda) tijekom iduće dvije godine, zatim godišnja izvješća naredne dvije godine te nakon toga izvješće svake tri godine.
The CVMP at their meeting on 14-16 May 2013 decided that one further renewal was required for the centrally authorised product Reconcile.
CVMP je na svom sastanku od 14.-16. svibnja 2013. odlučio da je potrebno jedno dodatno produljenje za općenito odobreni proizvod Reconcile.
The CVMP at their meeting on 8-10 April 2014 agreed that as the product with the revised inactivation process is only on the market in the EU/EEA since December 2012 and new quality specifications have been implemented in 2013 to prevent serious safety issues observed in the field, an assessment of the full impact of these changes is not possible at this moment.
CVMP je na sastanku održanom od 8. do 10. travnja 2014. odlučio da, s obzirom da je proizvod s revidiranim procesom inaktivacije dostupan samo na tržištu EU/EEA od prosinca 2012., a nove kvalitativne specifikacije su uvedene 2013., kako bi se spriječili ozbiljni sigurnosni problemi koji su uočeni na terenu, procjena cjelovitog učinka ovih promjena u ovom trenutku nije moguća.
The CVMP concluded that the benefits of Nexgard Spectra exceed the risks for the approved indications and recommended that Nexgard Spectra be given a marketing authorisation.
CVMP je odlučio da koristi od VMP-a Nexgard Spectra nadmašuju s njim povezane rizike za odobrene indikacije i preporučio je izdavanje odobrenja za stavljanje u promet VMP-a Nexgard Spectra.
The CVMP concluded that the benefits of ProZinc exceed the risks for the approved indication and recommended that ProZinc be given a marketing authorisation.
CVMP zaključio je da koristi VMP-a ProZinc nadmašuju rizike za odobrene indikacije i preporučio je da se odobrenje za stavljanje VMP-a u promet dodijeli VMP-u ProZinc.
The CVMP considered that, in accordance with European Union requirements, Rheumocam has been shown to be bioequivalent to Metacam.
CVMP je odredio da je u skladu sa zahtjevima Europske unije dokazano da je Rheumocam bioekvivalentan Metacamu.
The Cyanokit vial is to be rocked or inverted for at least 1 minute to mix the solution.
Bočicu Cyanokita treba lagano ljuljati ili okretati tijekom najmanje 1 minute kako bi se promiješala otopina.
The cycles were repeated every 3 weeks for 3 cycles.
Liječenje se primjenjivalo svaka 3 tjedna tijekom 3 ciklusa.
The cycles were repeated every 3 weeks for 3 cycles.
Liječenje se primjenjivalo svaka 3 tjedna, tijekom 3 ciklusa.
The cyclo-oxygenase enzyme (COX) is present in two isoforms.
Enzim ciklooksigenaza (COX) prisutan je u dva izoforma.
The cyclooxygenase 1 enzyme (COX-1) which has protective functions, e.g. in the digestive tract and kidneys, is not inhibited by robenacoxib.
Enzim ciklooksigenaza 1 (COX-1) koji ima zaštitne funkcije, primjerice u probavnom traktu i bubrezima nije inhibiran robenakoksibom.
The cyclooxygenase enzyme (COX) is present in two forms.
Enzim ciklooksigenaza (COX) javlja se u dva oblika.
The cylinders may be discarded with the bottle after use.
Nakon uporabe spremnici se mogu baciti zajedno s bocom.
The CYP2C19 inhibitor omeprazole (40 mg q.d.) did not give rise to a clinically significant change in lacosamide exposure.
Omeprazol (40 mg na dan), koji je inhibitor CYP2C19, nije prouzročio klinički značajnu promjenu izloženosti lakozamidu.
The cytotoxicity of MTIC is thought to be due primarily to alkylation at the O6 position of guanine with additional alkylation also occurring at the N7 position.
Smatra se da je za citotoksičnost MTIC-a primarno odgovorna alkilacija na položaju gvanina O6, uz dodatnu alkilaciju na položaju N7.
The cytotoxicity of MTIC is thought to be due primarily to alkylation at the O6 position of guanine with additional alkylation also occurring at the N7 position.
Smatra se da je za citotoksičnost MTIC-a primarno odgovorna alkilacija na položaju O6 gvanina, uz dodatnu alkilaciju na položaju N7.
The cytotoxicity of MTIC is thought to be due primarily to alkylation at the O6 position of guanine with additional alkylation also occurring at the N7 position.
Smatra se da je za citotoksičnost MTIC-a primarno odgovorna alkilacija na položaju O6gvanina, uz dodatnu alkilaciju na položaju N7.
The cytotoxicity of MTIC is thought to be dueprimarily to alkylation at the O6 position of guanine with additional alkylation also occurring at the N7 position.
Smatra se da je za citotoksičnost MTIC-a primarno odgovorna alkilacija na položaju gvanina O6, uz dodatnu alkilaciju na položaju N7.
The cytotoxicity of MTIC is thought to be primarily due to alkylation of DNA mainly at the O6 and N7 positions of guanine.
Smatra se da je citotoksičnost MTIC-a prvenstveno posljedica alkilacije DNK većinom na položajima gvanina O6 i N7.
The dabigatran AUC and Cmax were increased by about 60 % and 50 %, respectively.
AUC i Cmax dabigatrana povećali su se za oko 60 % i 50 %.
The dabigatran geometric mean trough concentration, measured at trough in the morning, at the end of the dosing interval (i.e.
Geometrijska srednja minimalna koncentracija dabigatrana, mjerena pri minimalnim vrijednostima ujutro, na kraju dozirnog intervala (tj.
The dabigatran geometric mean trough concentration, measured at trough in the morning, at the end of the dosing interval (i.e.
Geometrijska srednja najniža koncentracija dabigatrana, mjerena pri minimalnim vrijednostima ujutro, na kraju dozirnog intervala (tj.
The dabigatran trough concentrations were about 20 % lower in patients with a body weight > 100 kg compared with 50-100 kg.
Minimalne koncentracije dabigatrana bile su oko 20 % niže u bolesnika s tjelesnom težinom > 100 kg u usporedbi s 50 - 100 kg.
The dabrafenib capsules are to be swallowed whole with water.
Kapsule dabrafeniba treba progutati cijele s vodom.
The dabrafenib monotherapy safety profile is based on data from five clinical studies and included 578 patients with melanoma.
Sigurnosni profil dabrafeniba kao monoterapije temelji se na podacima dobivenim iz pet kliničkih ispitivanja u kojima je bilo uključeno 578 bolesnika s melanomom.
The daily amount of asparaginase needed per patient can be diluted in a final volume of 50 – 250 ml sodium chloride 9 mg/ml (0.9 %) solution for injection.
Dnevnu količinu asparaginaze potrebnu bolesniku može se razrijediti do konačnog volumena u 50 do 250 ml otopine natrijevog klorida 9 mg/ml (0,9%) za injekciju.
The daily cataplexy rate (geometric means) was 0.52 at baseline and 0.18 at final visit for pitolisant and 0.43 at baseline and 0.39 at final visit for placebo, with a rate ration rR=0.38 [0.16 ; 0.93] (p=0.034).
Dnevna stopa katapleksije (geometrijske sredine) iznosila je za pitolizant 0,52 na početku i 0,18 na posljednjem dolasku u ispitivanju, a za placebo 0,43 na početku i 0,39 na posljednjem dolasku, s relativnom stopom rR=0,38 [0,16 ; 0,93] (p=0,034).
The daily dosage is administered in equally divided doses 3 times a day.
Dnevna doza se primjenjuje u ravnomjerno podijeljenim dozama 3 puta dnevno.
The daily dosage may be administered in 2 or 3 divided doses.
Dnevna doza može se razdijeliti u 2 ili 3 doze.
The daily dose depends on the child’s body surface area, and infusions are given over 10 hours.
Dnevna doza ovisi o tjelesnoj površini djeteta, a infuzije se primjenjuju tijekom razdoblja od 10 sati.
The daily dose depends on the patient’s body weight.
Dnevna doza ovisi o tjelesnoj težini bolesnika.
The daily dose is 10 mL suspension (2 g of the medicine) taken as 2 separate doses.
Dnevna doza je 10 ml suspenzije (2 g lijeka), koja se uzima u 2 odvojene doze.
The daily dose is 12 capsules (3 g of the medicine) taken as 2 separate doses.
Dnevna doza je 12 kapsula (3 g lijeka) koje se uzimaju u 2 odvojene doze.
The daily dose is 15 mL suspension (3 g of the medicine) taken as 2 separate doses.
Dnevna doza je 15 ml suspenzije (3 g lijeka), koja se uzima u 2 odvojene doze.
The daily dose is 2 g of the medicine taken as 2 separate doses.
Dnevna doza je 2 g lijeka, u dvije odvojene doze.
The daily dose is 2 g of the medicine taken as 2 separate doses.
Dnevna doza je 2 grama lijeka, u 2 odvojene doze.
The daily dose is 4 tablets (2 g of the medicine) taken as 2 separate doses.
Dnevna doza je 4 tablete (2 g lijeka) koje se uzimaju u 2 odvojene doze.
The daily dose is 4 tablets (2 g of the medicine) taken as 2 separate doses.
Dnevna doza je 4 tablete (2 g lijeka), koje se uzimaju u 2 odvojene doze.
The daily dose is 6 tablets (3 g of the medicine) taken as 2 separate doses.
Dnevna doza je 6 tableta (3 g lijeka) koje se uzimaju u 2 odvojene doze.
The daily dose is 8 capsules (2 g of the medicine) taken as 2 separate doses.
Dnevna doza je 8 kapsula (2 g lijeka) koje se uzimaju u 2 odvojene doze.
The daily dose is between 5 and 15 mg per kg body weight, adjusted for each patient according to the state of their bile acid, with a minimum daily dose of 50 mg and a maximum of
Dnevna doza je između 5 i 15 mg po kg tjelesne težine prilagođena za svakog bolesnika u skladu sa
The daily dose is chosen and adjusted during treatment for each patient depending on the patient’s levels of bile acids in their blood and urine and their liver function.
Dnevna se doza odabire za svakog bolesnika i prilagođava mu se tijekom liječenja ovisno o razinama žučnih kiselina u krvi i urinu te funkciji njihove jetre.
The daily dose is to be modified as needed according to the dose/toxicity management plan.
Dnevna doza prilagođava se po potrebi, sukladno planu kontroliranja omjera doze i toksičnosti.
The daily dose is to be taken divided into 3 equal doses.
Dnevna doza se uzima podijeljena u 3 jednake doze.
The daily dose is to be taken divided into 3 equal doses.
Dnevna doza treba se uzeti podijeljena na 3 jednake doze.
The daily dose is to be taken divided into 3 equal doses.
Ukupna dnevna doza se uzima podijeljena u 3 jednake doze.
The daily dose may be divided if it consists of more than one capsule in order to mimic the continuous production of cholic acid in the body, and to reduce the number of capsules that need to be taken per administration.
Dnevna doza može se rasporediti tijekom dana, ako se sastoji od više od jedne kapsule, kako bi se oponašalo kontinuirano stvaranje kolatne kiseline u tijelu te se smanjio broj kapsula koji se mora uzeti prilikom svake primjene lijeka.
The daily dose may be lowered if needed to reduce side effects.
Dnevna doza može biti smanjenja ako je potrebno radi ublažavanja nuspojava.
The daily dose of AMMONAPS will be calculated from your protein tolerance, diet and body weight or body surface.
Dnevna doza AMMONAPS granula izračunava se prema Vašoj toleranciji na proteine, prehrani i tjelesnoj težini ili površini tijela.
the daily dose of ketoconazole should not exceed 200 mg.
Kada se zahtijeva istodobna primjena, dnevna doza ketokonazola ne smije prelaziti 200 mg.
The daily dose of levodopa should be reduced by about 10–30% by extending the dosing intervals and/or by reducing the amount of levodopa per dose, according to the clinical condition of the patient.
Dnevnu dozu levodope treba smanjiti za oko 10-30%, što se postiže produljenjem intervala doziranja i/ili smanjenjem količine levodope po dozi, u skladu s kliničkim stanjem bolesnika.
The daily dose of Olazax Disperzi is between 5 mg and 20 mg.
Dnevna doza lijeka Olazax Disperzi iznosi između 5mg i 20 mg.
The daily dose of PHEBURANE will be based on your body weight or body surface and adjusted according to your protein tolerance and diet.
Dnevna doza PHEBURANEA temeljit će se na Vašoj tjelesnoj težini i tjelesnoj površini i bit će prilagođena prema Vašoj toleranciji na proteine i dijeti.
The daily dose of Ravicti depends on the patient’s diet, height and weight.
Dnevna doza lijeka Ravicti ovisi o prehrani bolesnika, njegovoj visini i težini.
The daily dose of Revolade should not exceed 100 mg.
Dnevna doza lijeka Revolade ne smije premašiti 100 mg.
The daily dose of rifabutin
Dnevnu dozu rifabutina mora se
The daily dose of rifabutin
rifabutina u režimima u kojima se
The daily dose should be individually adjusted according to the patient’s estimated urea synthetic capacity, if any, amino acid profile, protein tolerance and the daily dietary protein intake needed to promote growth and development.
Dnevnu dozu treba individualno prilagoditi sukladno procijenjenom kapacitetu sinteze ureje bolesnika, ukoliko je ima, profilu aminokiselina, toleranciji proteina i dnevnom unosu proteina prehranom, potrebnom za poticanje rasta i razvoja.
The daily dose should be individually adjusted according to the patient’s protein tolerance and the daily dietary protein intake needed to promote growth and development.
Dnevnu dozu treba individualno prilagoditi prema bolesnikovoj toleranciji proteina i dnevnom unosu proteina hranom potrebnom za podržavanje rasta i razvoja djeteta.
The daily dose should be individually adjusted according to the patient’s protein tolerance and the daily dietary protein intake needed to promote growth and development.
Dnevnu dozu treba prilagoditi pojedinom bolesniku, obzirom na toleranciju proteina i dnevni unos proteina hranom, potreban za poticanje rasta i razvoja.
The daily dose should be individually adjusted according to the patient’s protein tolerance and the daily dietary protein intake needed.
Dnevnu dozu treba individualno prilagoditi prema bolesnikovom podnošenju proteina i potrebnom dnevnom unosu proteina prehranom.
The daily dose should be reduced by half in patients with moderate or severely reduced kidney function.
Kod bolesnika s umjerenim i teškim oštećenjem funkcije bubrega dnevnu dozu treba smanjiti za 50%.
The daily dose should be reduced in steps of 2 mg/24 h with a dose reduction preferably every other day, until complete withdrawal of Leganto (see section 4.4).
Dnevnu dozu treba postupno smanjivati za 2 mg/24 h, po mogućnosti svaki drugi dan, do potpunog prekida primjene Leganta(vidjeti dio 4.4).
The daily dose should not exceed 75 mg in ITP patients and 150 mg in severe aplastic anaemia patients.
Za osobe oboljele od ITP-a dnevna doza ne smije biti veća od 75 mg, a za bolesnike s teškom aplastičnom anemijom 150 mg.
The daily maintenance dose is between 200 mg and 400 mg.
Dnevna doza održavanja je između 200 mg i 400 mg.
The daily maintenance dose seldom exceeds 1.0 mg per day.
Dnevna doza održavanja rijetko prekoračuje 1,0 mg na dan.
The damage done to your nerves during this inflammation may be reversible, but as your disease progresses the damage may accumulate and become permanent.
Šteta koju Vaš živčani sustav pretrpi tijekom te upale može biti privremena, no s napretkom bolesti oštećenja se mogu nakupiti i postati trajna.
The dark purple colour of the solution, together with the amber vials makes a visual check for particulates impossible.
Tamnoljubičasta boja otopine i jantarna boja bočica onemogućuju vizualnu provjeru otopine na čestice.
The data available (see section 5.3) warrant caution in patients at risk of QT prolongation (long congenital QT, hypokalaemia).
Dostupni podaci (vidjeti dio 5.3) upućuju na oprez u bolesnika s rizikom od produljenja QT-intervala (urođeni dugi QT, hipokalijemija).
The data available from a rat embrofetal development study, where animals were given sodium aminosalicylate (3.85 to 385 mg/kg) were limited.
Podaci dostupni iz ispitivanja embrio-fetalnog razvoja u štakora, u kojima je životinjama davan natrij aminosalicilat (3,85 do 385 mg/kg), bili su ograničeni.
The data below summarizes the frequencies of the adverse reactions that were recorded following vaccination during clinical trials and worldwide post-marketing experience, using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1000); very rare (<1/10,000), not known (cannot be estimated from available data).
Dolje navedeni podaci sažeto prikazuju učestalost nuspojava koje su zabilježene nakon cijepljenja tijekom kliničkih ispitivanja i postmarketinške primjene širom svijeta, prema sljedećim kategorijama: vrlo često ( ≥ 1/10); često ( ≥ 1/100 do < 1/10); manje često ( ≥ 1/1 000 do < 1/100); rijetko ( ≥ 1/10 000 do < 1/1 000); vrlo rijetko ( < 1/10 000); nepoznato (ne može se utvrditi iz dostupnih podataka).
The data collected suggests that Parkinson’s disease, and not any medicinal products in particular, is associated with a higher risk of skin cancer (not exclusively melanoma).
Prikupljeni podaci upućuju na to da je Parkinsonova bolest, a ne neki određeni lijekovi, povezana s većim rizikom od karcinoma kože (ne isključivo melanoma).
The data described below reflect exposure of 162 Cushing’s disease patients to Signifor in the phase III study.
Podaci opisani u nastavku odnose se na izloženost lijeku Signifor u 162 bolesnika s Cushingovom bolešću u ispitivanju faze III.
The data described below reflect exposure to Tasigna in 279 patients from a randomised Phase III study in patients with newly diagnosed Ph+ CML in chronic phase treated with 300 mg of nilotinib twice daily.
Podaci navedeni u nastavku prikazuju izloženost Tasigni u 279 bolesnika iz randomiziranog ispitivanja faze III u novodijagnosticiranih bolesnika s KML-om u kroničnoj fazi liječenih dozom od 300 mg nilotiniba dva puta na dan.
The data described below reflect exposure to Tasigna in a total of 717 patients from a randomised Phase III study in patients with newly diagnosed Ph+ CML in chronic phase treated at the recommended dose of 300 mg twice daily (n=279) and from an open-label multicentre Phase II study in patients with imatinib-resistant or intolerant CML in chronic phase (n=321) and accelerated phase (n=137) treated at the recommended dose of 400 mg twice daily.
Podaci navedeni u nastavku prikazuju izloženost Tasigni u ukupno 717 bolesnika iz randomiziranog ispitivanja faze III u novodijagnosticiranih bolesnika s KML-om u kroničnoj fazi liječenih preporučenom dozom od 300 mg dva puta na dan (n=279) i iz otvorenog multicentričnog ispitivanja faze II u bolesnika s KML-om u kroničnoj (n=321) i ubrzanoj fazi (n=137) s rezistencijom ili intolerancijom na imatinib, a koji su liječeni preporučenom dozom od 400 mg dva puta na dan.